{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:26:17Z","timestamp":1787725577323,"version":"build-2784847793"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000005","name":"US Department of Defense","doi-asserted-by":"publisher","award":["W81XH-16-110385"],"award-info":[{"award-number":["W81XH-16-110385"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.cellimm.2024.104805","type":"journal-article","created":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T11:19:44Z","timestamp":1704712784000},"page":"104805","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["PIM kinase inhibitor AZD1208 in conjunction with Th1 cytokines potentiate death of breast cancer cells in vitro while also maximizing suppression of tumor growth in vivo when combined with immunotherapy"],"prefix":"10.1016","volume":"397-398","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8703-7767","authenticated-orcid":false,"given":"Ariel","family":"Anwar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carissa","family":"Lepore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Czerniecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary K.","family":"Koski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2359-4342","authenticated-orcid":false,"given":"Loral E.","family":"Showalter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Pt 3","key":"10.1016\/j.cellimm.2024.104805_b0005","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.mce.2014.11.015","article-title":"Estrogen receptors in breast carcinogenesis and endocrine therapy","volume":"418","author":"Huang","year":"2015","journal-title":"Mol. Cell. Endocrinol."},{"key":"10.1016\/j.cellimm.2024.104805_b0010","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2325\/jbcs.971","article-title":"Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?","volume":"14","author":"Ito","year":"2007","journal-title":"Breast Cancer"},{"key":"10.1016\/j.cellimm.2024.104805_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106156","article-title":"Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia","volume":"178","author":"Roskoski","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.cellimm.2024.104805_b0020","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.2165\/00003495-200666120-00004","article-title":"Monoclonal antibody-based targeted therapy in breast cancer: current status and future directions","volume":"66","author":"Bernard-Marty","year":"2006","journal-title":"Drugs"},{"key":"10.1016\/j.cellimm.2024.104805_b0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.cellimm.2024.104805_b0030","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.3390\/curroncol29050247","article-title":"Immune Checkpoint Inhibitors in Cancer Therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.cellimm.2024.104805_b0035","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.795164","article-title":"Recent Advances in Solid Tumor CAR-T Cell Therapy: Driving Tumor Cells From Hero to Zero?","volume":"13","author":"Safarzadeh Kozani","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.cellimm.2024.104805_b0040","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/nature11824","article-title":"T-helper-1-cell cytokines drive cancer into senescence","volume":"494","author":"Braum\u00fcller","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2024.104805_b0045","doi-asserted-by":"crossref","first-page":"6006","DOI":"10.18632\/oncotarget.10298","article-title":"T-helper 1-type cytokines induce apoptosis and loss of HER-family oncodriver expression in murine and human breast cancer cells","volume":"10","author":"Namjoshi","year":"2019","journal-title":"Oncotarget"},{"key":"10.1016\/j.cellimm.2024.104805_b0050","doi-asserted-by":"crossref","first-page":"23058","DOI":"10.18632\/oncotarget.25208","article-title":"Oncodriver inhibition and CD4(+) Th1 cytokines cooperate through Stat1 activation to induce tumor senescence and apoptosis in HER2+ and triple negative breast cancer: implications for combining immune and targeted therapies","volume":"9","author":"Rosemblit","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.cellimm.2024.104805_b0055","doi-asserted-by":"crossref","first-page":"e1207032","DOI":"10.1080\/2162402X.2016.1207032","article-title":"Addition of anti-estrogen therapy to anti-HER2 dendritic cell vaccination improves regional nodal immune response and pathologic complete response rate in patients with ER(pos)\/HER2(pos) early breast cancer","volume":"6","author":"Lowenfeld","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.cellimm.2024.104805_b0060","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.drup.2011.04.002","article-title":"The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms","volume":"14","author":"Isaac","year":"2011","journal-title":"Drug Resist. Updat."},{"key":"10.1016\/j.cellimm.2024.104805_b0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2021.129995","article-title":"Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects","volume":"1865","author":"Rathi","year":"2021","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.cellimm.2024.104805_b0070","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pharmthera.2015.03.001","article-title":"PIM kinase (and Akt) biology and signaling in tumors","volume":"151","author":"Warfel","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.cellimm.2024.104805_b0075","first-page":"4085","article-title":"The role of Pim kinase in immunomodulation","volume":"10","author":"Liu","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.cellimm.2024.104805_b0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218127","article-title":"MYC Targets Scores Are Associated with Cancer Aggressiveness and Poor Survival in ER-Positive Primary and Metastatic Breast Cancer","volume":"21","author":"Schulze","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.cellimm.2024.104805_b0085","doi-asserted-by":"crossref","first-page":"6613","DOI":"10.1038\/sj.onc.1204086","article-title":"STAT proteins: novel molecular targets for cancer drug discovery","volume":"19","author":"Turkson","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.cellimm.2024.104805_b0090","doi-asserted-by":"crossref","first-page":"4599","DOI":"10.1016\/j.bmcl.2012.05.098","article-title":"Discovery of novel benzylidene-1,3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases","volume":"22","author":"Dakin","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.cellimm.2024.104805_b0095","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2013-04-495366","article-title":"AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia","volume":"123","author":"Keeton","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2024.104805_b0100","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41416-018-0082-1","article-title":"Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers","volume":"118","author":"Cortes","year":"2018","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cellimm.2024.104805_b0105","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.4049\/jimmunol.165.9.5133","article-title":"DNA vaccination against rat her-2\/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB\/c mice","volume":"165","author":"Rovero","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2024.104805_b0110","doi-asserted-by":"crossref","first-page":"e0210209","DOI":"10.1371\/journal.pone.0210209","article-title":"Th1 cytokines sensitize HER-expressing breast cancer cells to lapatinib","volume":"14","author":"Showalter","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.cellimm.2024.104805_b0115","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1182\/blood-2007-12-130138","article-title":"STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells","volume":"112","author":"Cohen","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2024.104805_b0120","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.18632\/oncotarget.27556","article-title":"Th1 cytokines in conjunction with pharmacological Akt inhibition potentiate apoptosis of breast cancer cells in vitro and suppress tumor growth in vivo","volume":"11","author":"Showalter","year":"2020","journal-title":"Oncotarget"},{"key":"10.1016\/j.cellimm.2024.104805_b0125","article-title":"Statin Drugs Plus Th1 Cytokines Potentiate Apoptosis and Ras Delocalization in Human Breast Cancer Lines and Combine with Dendritic Cell-Based Immunotherapy to Suppress Tumor Growth in a Mouse Model of HER-2(pos) Disease","volume":"8","author":"Oechsle","year":"2020","journal-title":"Vaccines (basel)"},{"key":"10.1016\/j.cellimm.2024.104805_b0130","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.nano.2011.09.010","article-title":"Induction of tumor-specific immunity by multi-epitope rat HER2\/neu-derived peptides encapsulated in LPD Nanoparticles","volume":"8","author":"Jalali","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.cellimm.2024.104805_b0135","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.4049\/jimmunol.159.3.1336","article-title":"Peptides derived from a wild-type murine proto-oncogene c-erbB-2\/HER2\/neu can induce CTL and tumor suppression in syngeneic hosts","volume":"159","author":"Nagata","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2024.104805_b0140","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.4049\/jimmunol.159.8.3823","article-title":"Calcium ionophore-treated peripheral blood monocytes and dendritic cells rapidly display characteristics of activated dendritic cells","volume":"159","author":"Czerniecki","year":"1997","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2024.104805_b0145","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1590\/1414-431X20143437","article-title":"Trypan blue exclusion assay by flow cytometry","volume":"47","author":"Avelar-Freitas","year":"2014","journal-title":"Braz. J. Med. Biol. Res."},{"key":"10.1016\/j.cellimm.2024.104805_b0150","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.ymthe.2020.12.037","article-title":"Th1 cytokine interferon gamma improves response in HER2 breast cancer by modulating the ubiquitin proteasomal pathway","volume":"29","author":"Jia","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.cellimm.2024.104805_b0155","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1365-2567.2005.02201.x","article-title":"Expression of human pim family genes is selectively up-regulated by cytokines promoting T helper type 1, but not T helper type 2, cell differentiation","volume":"116","author":"Aho","year":"2005","journal-title":"Immunology"},{"key":"10.1016\/j.cellimm.2024.104805_b0160","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1074\/jbc.M112.361709","article-title":"Proviral integration site for Moloney murine leukemia virus (PIM) kinases promote human T helper 1 cell differentiation","volume":"288","author":"Tahvanainen","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.cellimm.2024.104805_b0165","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1158\/0008-5472.CAN-06-4038","article-title":"Targeting HER-2\/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion","volume":"67","author":"Czerniecki","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2024.104805_b0170","doi-asserted-by":"crossref","first-page":"8818393","DOI":"10.1155\/2021\/8818393","article-title":"Sunitinib Combined with Th1 Cytokines Potentiates Apoptosis in Human Breast Cancer Cells and Suppresses Tumor Growth in a Murine Model of HER-2(pos) Breast Cancer","volume":"2021","author":"Ghimirey","year":"2021","journal-title":"Int. J. Breast Cancer"},{"key":"10.1016\/j.cellimm.2024.104805_b0175","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.cellimm.2011.10.011","article-title":"The role of PIM kinases in human and mouse CD4+ T cell activation and inflammatory bowel disease","volume":"272","author":"Jackson","year":"2012","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.cellimm.2024.104805_b0180","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1172\/JCI95407","article-title":"PIM-2 protein kinase negatively regulates T cell responses in transplantation and tumor immunity","volume":"128","author":"Daenthanasanmak","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.cellimm.2024.104805_b0185","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1093\/clinids\/13.5.973","article-title":"Interferon-gamma in the management of chronic granulomatous disease","volume":"13","author":"Gallin","year":"1991","journal-title":"Rev. Infect. Dis."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000887492400008X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000887492400008X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T18:24:16Z","timestamp":1762107856000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000887492400008X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":37,"alternative-id":["S000887492400008X"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2024.104805","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PIM kinase inhibitor AZD1208 in conjunction with Th1 cytokines potentiate death of breast cancer cellsin vitrowhile also maximizing suppression of tumor growthin vivo when combined with immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2024.104805","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104805"}}